Rouslan Kotchetkov

11PUBLICATIONS
2CO-AUTHORS
Disease surveillanceOncology and carcinogenesis not elsewhere classifiedHaematologyInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 15, 2026
Azacitidine Is Well-Tolerated and Is Associated with High Response Rate in Elderly Patients with Higher-Risk Myelodysplastic Syndromes: A Single Center Observational Study.

|Mar 14, 2026
Addition of Venetoclax to Azacitidine Did Not Improve Survival in Acute Myeloid Leukemia and Was Not Well Tolerated: Real World Experience.

David Yanni, Nupur Krishnan, Rouslan Kotchetkov

|Aug 06, 2025
Cyclic Thrombocytopenia Treated With Platelet Transfusion and Oral Preparation Containing Hyaluronic Acid (Oralvisc).

M Benjamin, R Kotchetkov

|Dec 22, 2022
Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.

Rouslan Kotchetkov, Ian R Drennan, David Susman

|Mar 20, 2021
Reply to: Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein.

Rouslan Kotchetkov, David Susman, Divaya Bhutani

|Feb 17, 2021
Anticoagulation and bone marrow biopsy: is it safe to proceed?

Cameron Moore, Rouslan Kotchetkov

Pageof 2

Frequent Collaborators

2 joint publications

David Yanni

1 joint publications

Nupur Krishnan